Low versus null HER2 tumour expression in "HER2-negative" breast cancer: long-term outcomes based on phenotypes
Por:
Barco, I, González, C, García-Font, M, Fernández, AG, Fraile, M, Tarroch, X, Morlius, X, Vidal, M, González, S, Mitru, CB, Vallejo, E, Molina, G, Torras, M and Chabrera, C
Publicada:
1 sep 2025
Ahead of Print:
1 abr 2025
Resumen:
Background Two new categories of breast cancer (BC) have been proposed among HER2-negative patients: HER2 0 + and HER2-low breast cancer. We combined these two categories with Perou's classification. We aimed to identify potential differences in clinicopathological features and prognosis using a new, unofficial classification: Luminal A HER2 0 + , Luminal A HER2-Low, Luminal B HER2 0 + , Luminal B HER2- Low, Triple Negative HER2 0 + , and Triple Negative HER2-Low. Patients and methods We conducted a retrospective analysis of our database from January 1, 2005, to December 31, 2018. Cox Regression served as the basis for our study. Results We identified 1704 BC tumor cases from 1,639 HER2-negative patients (65 had bilateral BC). Among these, 608 cases were HER2 0 + , and 1096 were HER2-Low (aggregate). The median follow-up period was 120 months after surgery. None of the patients received anti-HER2 therapy.Case distribution was as follows: Luminal A HER2 0 + : 259. Luminal A HER2-low: 501. Luminal B HER2 0 + : 219. Luminal B HER2-low: 499. Triple-Negative HER2 0 + : 130. Triple-Negative HER2-low: 96. There was a 12.2% excess in the Triple Negative rate in the HER2 0 + group, compared with the HER2 Low group (aggregate), which was highly significant (Chisquare, p < 0.01). Although the HER2 0 + versus HER2 Low Hazard Ratio (HR) for Specific Mortality was of borderline significance:1.39 (IC 1.00-1.92, p = 0.049), the TN imbalance complicated a direct comparison between the two groups. After stratification using the noncanonical classification, the HR was highly significant, but only for the Luminal A subtype: 2.28 (IC 1.09-4.36, p = 0.028). Results We identified 1704 BC tumor cases from 1,639 HER2-negative patients (65 had bilateral BC). Among these, 608 cases were HER2 0 + , and 1096 were HER2-Low (aggregate). The median follow-up period was 120 months after surgery. None of the patients received anti-HER2 therapy.Case distribution was as follows: Luminal A HER2 0 + : 259. Luminal A HER2-low: 501. Luminal B HER2 0 + : 219. Luminal B HER2-low: 499. Triple-Negative HER2 0 + : 130. Triple-Negative HER2-low: 96. There was a 12.2% excess in the Triple Negative rate in the HER2 0 + group, compared with the HER2 Low group (aggregate), which was highly significant (Chisquare, p < 0.01). Although the HER2 0 + versus HER2 Low Hazard Ratio (HR) for Specific Mortality was of borderline significance:1.39 (IC 1.00-1.92, p = 0.049), the TN imbalance complicated a direct comparison between the two groups. After stratification using the noncanonical classification, the HR was highly significant, but only for the Luminal A subtype: 2.28 (IC 1.09-4.36, p = 0.028). Comments In the noncanonical classification, the effect of the unbalanced Triple-Negative proportions disappeared, and a significant finding emerged: HER2 0 + status had a negative prognostic influence exclusively in Luminal A patients.
Filiaciones:
Barco, I:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Breast Unit,Dept Gynecol, Terrassa, Barcelona, Spain
González, C:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Dept Pathol, Terrassa, Barcelona, Spain
García-Font, M:
Univ Int Catalunya, Barcelona, Spain
Fernández, AG:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Breast Unit,Dept Gynecol, Terrassa, Barcelona, Spain
Fraile, M:
Univ Hosp Mutua Terrassa, Nucl Med Dept, Barcelona, Spain
Univ Hosp Germans Trias I Pujol, Barcelona, Spain
Tarroch, X:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Dept Pathol, Terrassa, Barcelona, Spain
Morlius, X:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Dept Pathol, Terrassa, Barcelona, Spain
:
Catalan Inst Hlth, Dept Breastfeeding, Sexual & Reprod Hlth Care Program, Barcelona, Spain
González, S:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Breast Unit,Dept Oncol, Terrassa, Barcelona, Spain
Mitru, CB:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Breast Unit,Dept Surg, Terrassa, Barcelona, Spain
Vallejo, E:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Breast Unit,Dept Gynecol, Terrassa, Barcelona, Spain
Molina, G:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Breast Unit,Dept Gynecol, Terrassa, Barcelona, Spain
Torras, M:
Univ Barcelona, Hosp Mutua Terrassa, Res Fdn Mutua Terrassa, Breast Unit,Dept Gynecol, Terrassa, Barcelona, Spain
Chabrera, C:
Univ Pompeu Fabra, Res Grp Attent Chron & Innovat Hlth GRACIS, Tecnocampus, Barcelona, Spain
|